Myeloperoxidase/MPO Antibody (392105) [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # FAB3174H

Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Immunocytochemistry, Immunohistochemistry, Western Blot
Label
HRP
Antibody Source
Monoclonal Mouse IgG2B Clone # 392105
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
E. coli-derived recombinant human Myeloperoxidase/MPO
Val279-Ser745
Accession # P05164
Val279-Ser745
Accession # P05164
Specificity
Detects human Myeloperoxidase/MPO in Western blots. No cross-reactivity with recombinant human Eosinophil Peroxidase is observed.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2B
Applications for Myeloperoxidase/MPO Antibody (392105) [HRP]
Application
Recommended Usage
Immunocytochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Myeloperoxidase/MPO
Alternate Names
MPO
Gene Symbol
MPO
Additional Myeloperoxidase/MPO Products
Product Documents for Myeloperoxidase/MPO Antibody (392105) [HRP]
Product Specific Notices for Myeloperoxidase/MPO Antibody (392105) [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...